Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Passage Bio Inc (Passage Bio) is a genetic medicines company that develops therapies for the treatment of neurodegenerative diseases. The company's pipeline product include PBFT02 treats frontotemporal dementia, amyotrophic lateral sclerosis and Alzheimer’s disease. The company also developing drugs for the treatment of Huntington’s Disease. Passage Bio works in collaboration with the University of Pennsylvania and its gene therapy program (GTP) for preclinical works. It operates through its manufacturing and global clinical distribution center is located at Hopewell, New Jersey. Passage Bio is headquartered in Philadelphia, Pennsylvania, the US.
Headquarters
United States of America
Address
One Commerce Square, 39th Floor, 2005 Market Street, Philadelphia, Pennsylvania, 19103
Website
www.passagebio.com
Telephone
1 267 8660311
No of Employees
24
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PASG (NASD)
EPS
XYZ
Net Income (2024)
XYZ
29.7%
(2024 vs 2023)
Market Cap*
$14.7M
* As of and is in US$
Passage Bio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| PBFT02: |
| Frontotemporal Dementia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In August, the company entered into agreements to out-license its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. |
| 2022 | Others | In August, the company announced that the first patient was dosed in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02. |
| 2022 | Regulatory Approval | In June, the company secured FDA Clearance of IND application for PBML04 for treatment of metachromatic leukodystrophy. |
Competitor Comparison
| Key Parameters | Passage Bio Inc | Arcturus Therapeutics Holdings Inc | Alector Inc | Taysha Gene Therapies Inc | Beacon Therapeutics (USA) Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Philadelphia | San Diego | San Francisco | Dallas | Alachua |
| State/Province | Pennsylvania | California | California | Texas | Florida |
| No. of Employees | 24 | 106 | 103 | 99 | 102 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Maxine Gowen, Ph.D. | Chairman | Executive Board | 2021 | 68 |
| William Chou, M.D | Director; President; Chief Executive Officer | Executive Board | 2022 | 53 |
| Kathleen Borthwick | Chief Financial Officer | Senior Management | 2024 | 50 |
| Sue Browne, PhD | Chief Scientific Officer | Senior Management | 2021 | - |
| Stuart Henderson | Chief Business Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer